Murali R - Search Results

1

Shared antigenic epitopes and pathobiological functions of anti-p185(her2/neu) monoclonal antibodies.

Zhang H, Wang Q, Montone KT, Peavey JE, Drebin JA, Greene MI, Murali R. Zhang H, et al. Among authors: murali r. Exp Mol Pathol. 1999 Sep;67(1):15-25. doi: 10.1006/exmp.1999.2266. Exp Mol Pathol. 1999. PMID: 10493889 Free article.

2

Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo.

Park BW, Zhang HT, Wu C, Berezov A, Zhang X, Dua R, Wang Q, Kao G, O'Rourke DM, Greene MI, Murali R. Park BW, et al. Among authors: murali r. Nat Biotechnol. 2000 Feb;18(2):194-8. doi: 10.1038/72651. Nat Biotechnol. 2000. PMID: 10657127

3

New perspectives on anti-HER2/neu therapeutics.

Zhang HT, Wang Q, Greene MI, Murali R. Zhang HT, et al. Among authors: murali r. Drug News Perspect. 2000 Aug;13(6):325-9. Drug News Perspect. 2000. PMID: 12937653

4

Structure-based approaches to inhibition of erbB receptors with peptide mimetics.

Berezov A, Greene MI, Murali R. Berezov A, et al. Among authors: murali r. Immunol Res. 2003;27(2-3):303-8. doi: 10.1385/IR:27:2-3:303. Immunol Res. 2003. PMID: 12857977 Review.

5

ErbB receptors: from oncogenes to targeted cancer therapies.

Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI. Zhang H, et al. Among authors: murali r. J Clin Invest. 2007 Aug;117(8):2051-8. doi: 10.1172/JCI32278. J Clin Invest. 2007. PMID: 17671639 Free PMC article. Review.

6

Targeting erbB receptors.

Cai Z, Zhang H, Liu J, Berezov A, Murali R, Wang Q, Greene MI. Cai Z, et al. Among authors: murali r. Semin Cell Dev Biol. 2010 Dec;21(9):961-6. doi: 10.1016/j.semcdb.2010.09.005. Epub 2010 Sep 17. Semin Cell Dev Biol. 2010. PMID: 20850557 Free PMC article. Review.

7

Structural analysis of p185c-neu and epidermal growth factor receptor tyrosine kinases: oligomerization of kinase domains.

Murali R, Brennan PJ, Kieber-Emmons T, Greene MI. Murali R, et al. Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6252-7. doi: 10.1073/pnas.93.13.6252. Proc Natl Acad Sci U S A. 1996. PMID: 8692801 Free PMC article.

8

Structure-based design of immunologically active therapeutic peptides.

Murali R, Greene MI. Murali R, et al. Immunol Res. 1998;17(1-2):163-9. doi: 10.1007/BF02786441. Immunol Res. 1998. PMID: 9479578 Review.

9

Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential.

Zhang HT, O'Rourke DM, Zhao H, Murali R, Mikami Y, Davis JG, Greene MI, Qian X. Zhang HT, et al. Among authors: murali r. Oncogene. 1998 Jun 4;16(22):2835-42. doi: 10.1038/sj.onc.1201820. Oncogene. 1998. PMID: 9671404

10

HER2/neu: mechanisms of dimerization/oligomerization.

Brennan PJ, Kumagai T, Berezov A, Murali R, Greene MI. Brennan PJ, et al. Among authors: murali r. Oncogene. 2000 Dec 11;19(53):6093-101. doi: 10.1038/sj.onc.1203967. Oncogene. 2000. PMID: 11156522 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

527 results

Search Page